Hennion & Walsh Asset Management Inc. Acquires 27,937 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Hennion & Walsh Asset Management Inc. increased its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 32.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 112,867 shares of the company’s stock after acquiring an additional 27,937 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.17% of Amylyx Pharmaceuticals worth $321,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in AMLX. Adage Capital Partners GP L.L.C. lifted its position in shares of Amylyx Pharmaceuticals by 121.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,700,200 shares of the company’s stock worth $31,131,000 after purchasing an additional 932,000 shares during the period. Franklin Resources Inc. boosted its position in Amylyx Pharmaceuticals by 114.4% during the 4th quarter. Franklin Resources Inc. now owns 1,325,001 shares of the company’s stock valued at $19,504,000 after acquiring an additional 707,134 shares in the last quarter. Hudson Bay Capital Management LP grew its holdings in shares of Amylyx Pharmaceuticals by 134.5% during the 3rd quarter. Hudson Bay Capital Management LP now owns 682,223 shares of the company’s stock worth $12,492,000 after acquiring an additional 391,323 shares during the period. Trexquant Investment LP bought a new position in shares of Amylyx Pharmaceuticals in the 4th quarter worth approximately $3,901,000. Finally, abrdn plc purchased a new position in Amylyx Pharmaceuticals during the fourth quarter valued at $2,878,000. Institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AMLX. SVB Leerink lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, March 11th. Leerink Partnrs lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. Evercore ISI restated an “in-line” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. Robert W. Baird cut Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Monday, March 11th. Finally, The Goldman Sachs Group reissued a “neutral” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Hold” and an average price target of $24.80.

Amylyx Pharmaceuticals Trading Up 1.7 %

Shares of AMLX opened at $1.77 on Thursday. The company has a market cap of $120.37 million, a price-to-earnings ratio of -1.65 and a beta of -0.64. The business’s fifty day simple moving average is $1.80 and its two-hundred day simple moving average is $7.88. Amylyx Pharmaceuticals, Inc. has a 12 month low of $1.58 and a 12 month high of $25.48.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of $0.24 by ($0.70). The business had revenue of $88.64 million during the quarter, compared to the consensus estimate of $113.26 million. Amylyx Pharmaceuticals had a positive return on equity of 4.14% and a negative net margin of 17.86%. During the same quarter in the previous year, the business posted $0.02 earnings per share. As a group, research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.36 EPS for the current year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.